Literature DB >> 17365904

Role of dietary phosphorus and degree of uremia in the development of renal bone disease in rats.

Line Oste1, Geert J Behets, Geert Dams, An R Bervoets, Rita L Marynissen, Hilde Geryl, Viviane O Van Hoof, Marc E De Broe, Patrick C D'Haese.   

Abstract

The remnant kidney rat model has been extensively used for the evaluation of bone changes due to uremia. The present study aimed to assess the effect of the dietary phosphorus availability and of the severity of renal failure on bone histomorphometric changes and various biochemical markers over time in this model. Chronic renal failure (CRF) was induced in male Wistar rats by 5/6th nephrectomy. Half of the number of animals received a standard rat diet (STD) (0.67% P, containing low bioavailable phosphorus of plant origin); the other animals were fed a high phosphorus diet (HPD) (0.93% P, containing inorganic phosphorus with high bioavailability). Every two weeks, blood and urine samples were collected. At sacrifice after 6 or 12 weeks, bone samples were taken for the measurement of histological and histodynamic parameters. Serum creatinine measurements indicated the development of mild to moderate renal failure in both diet groups. Phosphaturia was unexpectedly low in all animals that received the STD, indicating relative phosphorus depletion despite the normal dietary phosphorus content. In the HPD CRF group, a decrease in calcemia and a rise in phosphatemia were seen after 12 weeks of CRF, which were more pronounced in animals with higher serum creatinine. Serum iPTH levels were distinctly increased in CRF rats fed a HPD, especially those with more pronounced renal failure. Serum osteocalcin and to a lesser extend tartrate-resistant acid phosphatase and urinary pyridinoline and deoxypyridinoline crosslinks were higher in the CRF animals compared to the shams, particularly in the animals of the HPD group with more pronounced CRF. In both diet groups, the CRF animals had significantly higher amounts of osteoid compared to shams. Only the animals that received a HPD developed distinct histological signs of secondary hyperparathyroidism (sHPTH), that is, an increased bone formation rate, mineral apposition rate, osteoblast perimeter, and eroded perimeter. Again, this effect was most prominent in rats with more severe CRF. In conclusion, data of the present study indicate that in experimental studies using the remnant kidney rat model, both the dietary phosphorus bioavailability and the degree of renal failure in the development of hyperparathyroidism should be considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17365904     DOI: 10.1080/08860220601038637

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  4 in total

1.  Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide.

Authors:  N Fretellier; Jm Idée; P Bruneval; S Guerret; F Daubiné; G Jestin; C Factor; N Poveda; A Dencausse; F Massicot; O Laprévote; C Mandet; N Bouzian; M Port; C Corot
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

2.  Influence of Secondary Hyperparathyroidism Induced by Low Dietary Calcium, Vitamin D Deficiency, and Renal Failure on Circulating Rat PTH Molecular Forms.

Authors:  Pierre D'Amour; Louise Rousseau; Stephen Hornyak; Zan Yang; Tom Cantor
Journal:  Int J Endocrinol       Date:  2011-06-22       Impact factor: 3.257

3.  Mineral bone disorder in chronic kidney disease: head-to-head comparison of the 5/6 nephrectomy and adenine models.

Authors:  Guaraciaba O Ferrari; Juliana C Ferreira; Raquel T Cavallari; Katia R Neves; Luciene M dos Reis; Wagner V Dominguez; Elizabeth C Oliveira; Fabiana G Graciolli; Jutta Passlick-Deetjen; Vanda Jorgetti; Rosa M A Moysés
Journal:  BMC Nephrol       Date:  2014-05-03       Impact factor: 2.388

4.  A magnesium based phosphate binder reduces vascular calcification without affecting bone in chronic renal failure rats.

Authors:  Ellen Neven; Tineke M De Schutter; Geert Dams; Kristina Gundlach; Sonja Steppan; Janine Büchel; Jutta Passlick-Deetjen; Patrick C D'Haese; Geert J Behets
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.